Summary

PTPN22 rs2476601 (R620W) is the strongest non-HLA genetic risk factor for autoimmune disease — the A variant allele alters lymphocyte activation thresholds for both T and B cells, increasing risk for type 1 diabetes, rheumatoid arthritis, autoimmune thyroid disease, and lupus through a mechanism that affects how easily your immune cells trigger against self-antigens.

Genotype spectrum

GG (Arg620/Arg620)

Your lymphocyte activation threshold is set normally. T and B cell signalling brakes function as expected.

GA (Arg620/Trp620)

Your immune system runs with a slightly lower activation threshold. This means potentially faster immune responses to genuine threats — your T and B cells may be more sensitive to pathogenic signals.

AA (Trp620/Trp620)

This is one of the strongest single-gene autoimmune risk factors outside HLA. The good news: being rare and carrying it means that if you do develop an autoimmune condition, the mechanism is well-understood and treatments are advancing rapidly.

Practical takeaway

For GG Carriers (Reference)
• Standard immune health. No PTPN22-specific intervention.
For GA Carriers (One Risk Allele)

Immune regulation priorities:
• Gut health (high priority): Gut barrier integrity prevents bacterial antigens from entering systemic circulation and triggering molecular mimicry — a key autoimmune initiation mechanism. Daily targets: 30+ different plant foods per week, 25-35g fibre, fermented foods (yogurt, kefir, sauerkraut, kimchi). Minimise gut barrier disruptors: excess alcohol, chronic NSAID use, emulsifiers in ultra-processed foods.
• Vitamin D: Ensure sufficiency (>75 nmol/L). Vitamin D supports Treg function and dampens Th1/Th17 responses. Test annually; supplement as needed (typically 2000-4000 IU/day in temperate climates).
• Omega-3: 2-3g combined EPA/DHA daily. Supports resolution of inflammation and Treg function.
• Sleep: 7-9 hours. Sleep deprivation impairs Treg function and shifts immune balance toward autoimmunity.
• Stress management: Chronic stress → cortisol dysregulation → impaired immune regulation. Regular practice of stress management technique (exercise, meditation, nature exposure).

Monitoring:
• Know your family history for autoimmune conditions (T1D, RA, thyroid, lupus, coeliac, psoriasis).
• Thyroid function: if family history positive, baseline TSH and anti-TPO antibodies.
• Joint symptoms (morning stiffness >30 min, swelling): prompt GP evaluation.
For AA Carriers (Homozygous — Very Rare)

Everything above, plus:
• Annual thyroid screening: TSH + anti-TPO even without symptoms. Autoimmune thyroid disease (Hashimoto's, Graves') is the most common autoimmune condition and frequently the first to present.
• Annual metabolic screening: Fasting glucose, HbA1c. T1D risk is substantially elevated. Note: LADA (latent autoimmune diabetes of adults) presents later than classic T1D and can be misdiagnosed as T2D.
• Proactive GP relationship: Establish with your GP that you carry a significant autoimmune risk variant. This ensures that ambiguous symptoms (fatigue, joint stiffness, skin changes) get appropriate workup rather than dismissal.
• Smoking is absolutely contraindicated. Smoking + PTPN22 risk genotype is a well-do

Evidence detail

What This Gene Does

PTPN22 encodes a protein called Lyp (lymphoid-specific phosphatase), which is a critical negative regulator of T cell receptor (TCR) and B cell receptor (BCR) signalling. When a T cell encounters an antigen presented by an antigen-presenting cell, the TCR initiates a signalling cascade that begins with the kinase Lck phosphorylating downstream targets. Lyp dephosphorylates these targets, dampening the signal and raising the threshold for T cell activation. In effect, Lyp acts as a brake on immune cell activation — preventing T and B cells from responding to weak or ambiguous signals (which is how self-tolerance is maintained).

The rs2476601 variant (G>A) causes an amino acid change at position 620: Arg620 (G, reference) to Trp620 (A, variant). This position is in the P1 domain of Lyp, which mediates its interaction with CSK (C-terminal Src kinase), another key negative regulator of TCR signalling. The R620W substitution disrupts the Lyp-CSK interaction.

Here's where it gets interesting: the mechanism has been debated for 20 years. The original interpretation (gain-of-function) suggested that R620W creates a more active phosphatase that over-suppresses TCR signalling, leading to defective negative selection in the thymus (autoreactive T cells escape deletion). More recent work supports a different model: R620W is actually a loss-of-function for the Lyp-CSK complex (the brake fails), but a gain-of-function for Lyp's intrinsic phosphatase activity. The net effect is altered — not simply increased or decreased — TCR signalling dynamics that impair central and peripheral tolerance. The bottom line: regardless of the mechanistic nuance, the 620W variant reproducibly increases autoimmune risk across multiple conditions.

Mechanism

T cell activation and the Lyp brake:

When a T cell receptor recognises an antigen:
1. Lck kinase phosphorylates the TCR's ITAMs (immunoreceptor tyrosine-based activation motifs).
2. ZAP-70 kinase binds phosphorylated ITAMs and phosphorylates downstream targets (LAT, SLP-76).
3. This activates PLCγ, calcium signalling, and ultimately the transcription factors NFAT, NF-κB, and AP-1 → T cell activation.

Lyp (PTPN22 protein) dephosphorylates Lck and ZAP-70, pulling the plug on this cascade. It works in complex with CSK, which independently inhibits Lck. Together, Lyp + CSK set the activation threshold — how strong a TCR signal needs to be for the T cell to commit to full activation.

What R620W changes:

The Arg→Trp substitution at position 620 disrupts the Lyp-CSK binding interface. The consequences:

1. Disrupted Lyp-CSK complex: Lyp can no longer efficiently partner with CSK. The coordinated negative regulation is impaired.
2. Altered intrinsic activity: R620W Lyp has higher intrinsic phosphatase activity (Vang 2005), but the CSK partnership loss changes when and where this activity is applied.
3. Net effect on T cells: TCR signalling dynamics are altered — not simply stronger or weaker, but differently calibrated. The threshold at which T cells distinguish "self" from "non-self" shifts.

In the thymus (central tolerance):
Developing T cells that react too strongly to self-antigens should be deleted (negative selection). Altered TCR signalling threshold means some autoreactive T cells that should be deleted instead survive and enter the periphery.

In the periphery (peripheral tolerance):
Mature T cells that encounter self-antigens in the absence of co-stimulation should become anergic (unresponsive). Altered signalling dynamics impair this tolerance mechanism too.

B cell effects:
Lyp also regulates BCR signalling. R620W carriers have more polyreactive B cells (Menard 2011) — B cells that produce antibodies capable of binding self-antigens. This explains why PTPN22 is associated with autoantibody-positive autoimmune conditions specifically.

The multi-hit model:
PTPN22 R620W lowers the immunological "guard" — it makes both T and B cell tolerance leakier. But autoimmune disease stil

PTPN22 Autoimmune

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (10)